WO2021137913A2 - 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto - Google Patents

4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto Download PDF

Info

Publication number
WO2021137913A2
WO2021137913A2 PCT/US2020/054857 US2020054857W WO2021137913A2 WO 2021137913 A2 WO2021137913 A2 WO 2021137913A2 US 2020054857 W US2020054857 W US 2020054857W WO 2021137913 A2 WO2021137913 A2 WO 2021137913A2
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
alkyl
amino
different
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/054857
Other languages
English (en)
French (fr)
Other versions
WO2021137913A3 (en
Inventor
George R. Painter
David Perryman
Gregory R. Bluemling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202410413848.0A priority Critical patent/CN118477090A/zh
Priority to US17/766,644 priority patent/US20240165143A1/en
Priority to JP2022521355A priority patent/JP2022551477A/ja
Priority to CN202080069960.7A priority patent/CN114867351B/zh
Priority to EP20908968.9A priority patent/EP4040965A4/en
Priority to AU2020418425A priority patent/AU2020418425A1/en
Priority to CA3153281A priority patent/CA3153281A1/en
Application filed by Emory University filed Critical Emory University
Publication of WO2021137913A2 publication Critical patent/WO2021137913A2/en
Publication of WO2021137913A3 publication Critical patent/WO2021137913A3/en
Anticipated expiration legal-status Critical
Priority to US19/292,470 priority patent/US20260102422A1/en
Priority to JP2025172129A priority patent/JP2026027247A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the disclosure relates to halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto.
  • the disclosure relates to the treatment or prophylaxis of viral infections, for example, tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picomaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.
  • tongaviridae bunyaviridae
  • arenaviridae coronaviridae
  • flaviviridae flaviviridae
  • picomaviridae Eastern, Western, and Venezuelan Equine Encephalitis
  • CHIK Chikungunya fever
  • Ebola Influenza
  • RSV Zika virus infections.
  • the causative agents for Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively) and Chikungunya fever (CHIK) are vector-home viruses (family Togaviridae, genus Alphavirus ) that can be transmitted to humans through mosquito bites.
  • the equine encephalitis viruses are CDC Category B pathogens, and the CHIK virus is Category C.
  • CHIK virus is Category C.
  • 2019-nCov belongs to betacoronavirus but is divergent from SARS and MERS.
  • the 2019-nCoV is a highly pathogenic human pathogen that relatively little is known about.
  • SARS-CoV- 2/2019-nCoV causes disease refered to a COVID-19.
  • COVID-19 can include severe respiratory disease in humans and appears to also cause neurological disease that includes dizziness, impaired consciousness, acute cerebrovascular disease, epilepsy, hyposmia, hypopsia, and neuralgia ( medRxiv , 2020, 1-26).
  • SARS-CoV-2 entry into the CNS may be promoted through viral interaction with ACE2 receptors after dissemination of the virus in the systemic circulation or across the cribriform plate. Additional studies are needed to further characterize the virus and to identify ways to prevent and treat disease.
  • halogen e.g. 4 ’-halogen
  • nucleosides optionally conjugated to a phosphorus oxide or salts thereof, prodrugs or conjugate compounds or salts thereof comprising an amino acid ester, lipid or a sphingolipid or derivative linked by a phosphorus oxide to a nucleotide or nucleoside.
  • the disclosure relates to a compound having Formula A, Formula A or a pharmaceutically acceptable salt, derivative, or prodrug thereof, as defined herein.
  • the disclosure contemplates derivatives of compounds disclosed herein, such as those containing one or more, the same or different, substituents.
  • the disclosure contemplates pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a compound disclosed herein.
  • the pharmaceutical composition is in the form of a tablet, capsule, pill, or aqueous buffer, such as a saline or phosphate buffer.
  • the disclosed pharmaceutical compositions can comprise a compound disclosed herein and a propellant.
  • the propellant is an aerosolizing propellant such as compressed air, ethanol, nitrogen, carbon dioxide, nitrous oxide, hydrofluoroalkanes (HFAs), 1,1,1,2,-tetrafluoroethane, 1, 1,1, 2, 3,3,3- heptafluoropropane or combinations thereof.
  • the disclosure contemplates a pressurized or unpressurized container comprising a compound or pharmaceutical composition as described herein.
  • the container is a manual pump spray, inhaler, meter-dosed inhaler, dry powder inhaler, nebulizer, vibrating mesh nebulizer, jet nebulizer, or ultrasonic wave nebulizer.
  • the disclosure relates to methods of increasing bioavailability for treating or preventing a viral infection comprising administering an effective amount of a compound or pharmaceutical composition disclosed herein to a subject in need thereof.
  • the disclosure relates to the use of a compound as described herein in the production of a medicament for the treatment or prevention of a viral infection, such as Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, or Zika virus infection.
  • a viral infection such as Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, or Zika virus infection.
  • the disclosure relates to methods of making compounds disclosed herein by mixing starting materials and reagents disclosed herein under conditions such that the compounds are formed.
  • Figure 2 shows stability of EIDD-02749 in water.
  • Figure 3 shows stability of EIDD-02749 in 0.1 N HC1.
  • Figure 5 shows stability of EIDD-02749 in pH 9 buffer.
  • Figure 6 shows triphosphate concentrations in Huh-7 cells incubated with EIDD- 02749 or a prodrug.
  • Figure 8 shows plasma PK curves from CD-I mice that received a single dose of EIDD-02749 at 50, 150, and 500 mg/kg PO or 10 mg/kg ip.
  • Figure 9 shows the change in body weight of AG129 mice dosed with 10, 30, and 100 mg/kg EIDD-02749 QD for 10 days.
  • Figure 10 shows plasma PK curves from CD-I mice that received a single dose of EIDD-02749 at 1.5, 5, 15, 50, 150, and 500 mg/kg PO or 10 mg/kg ip.
  • Figure 11 shows plasma PK curves from ferrets that received a single dose of EIDD- 02749 at 15 and 50 mg/kg PO.
  • Figure 12 shows plasma PK curves from Guinea pigs that received a single dose of EIDD-02749 at 5 and 50 mg/kg PO and 5 mg/kg i.v.
  • FIG. 13 shows concentrations of EIDD-02749 (ribonucleoside), EIDD-02986 (5’- monophosphate), and EIDD-02991 (5 ’-triphosphate) in tissues from CD-I mice that received a single oral dose of 5, 50, and 500 mg/kg EIDD-02749.
  • FIG 14 shows concentrations of EIDD-02749 (ribonucleoside), EIDD-02986 (5’- monophosphate), and EIDD-02991 (5 ’-triphosphate) in tissues from Guinea pigs that received a single oral dose of 50 mg/kg EIDD-02749.
  • Figure 15 shows the survival of AG129 mice infected with Tacaribe virus and treated with EIDD-02749 starting 2 hours before infection.
  • Figure 16 shows Day 9 viral titers in serum (Graph A); liver tissue (Graph B); spleen tissue (Graph C); and brain tissue (Graph D) tissues from AG129 mice infected with Tacaribe virus and treated with EIDD-02749.
  • Figure 17 shows the survival of AG129 mice infected with Tacaribe virus treated with EIDD-02749 starting at 2 hours, 1 Day, 3 Days, 5 Days, and 7 Days post infection.
  • Figure 18 shows Day 9 viral titers in tissues from AG129 mice infected with Tacaribe virus and treated with EIDD-02749 starting at 2 hours, 1 Day, 3 Days, 5 Days, and 7 Days post infection.
  • nucleosides optionally conjugated to a phosphorus oxide or salts thereof.
  • the disclosure relates to conjugate compounds or salts thereof comprising an amino acid ester, a lipid or a sphingolipid or derivative linked by a phosphorus oxide to a nucleotide or nucleoside.
  • the disclosure contemplates pharmaceutical compositions comprising these compounds for uses in treating infectious diseases, viral infections, and cancer.
  • the disclosure relates to phosphorus oxide prodrugs of 4’- halogen containing nucleosides for the treatment of positive-sense and negative-sense RNA viral infections through targeting of the virally encoded RNA-dependent RNA polymerase (RdRp).
  • This disclosure also provides the general use of lipids and sphingolipids to deliver nucleoside analogs for the treatment of infectious disease and cancer.
  • the sphingolipid is saturated or unsaturated 2-aminoalkyl or 2-aminooctadecane optionally substituted with one or more substituents. In certain embodiments, the sphingolipid derivative is saturated or unsaturated 2-aminooctadecane-3- ol optionally substituted with one or more substituents. In certain embodiments, the sphingolipid derivative is saturated or unsaturated 2-aminooctadecane-3,5-diol optionally substituted with one or more substituents. In certain embodiments, the disclosure contemplates pharmaceutical compositions comprising any of the compounds disclosed herein and a pharmaceutically acceptable excipient.
  • the pharmaceutical composition is in the form of a pill, capsule, tablet, or saline buffer comprising a saccharide.
  • the composition may contain a second active agent such as a pain reliever, anti-inflammatory agent, non-steroidal anti-inflammatory agent, anti-viral agent, anti-biotic, or anti-cancer agent.
  • the disclosure relates the methods of treating a viral infection comprising administering an effective amount of a pharmaceutical composition disclosed herein to a subject in need thereof.
  • the subject is a mammal, for example, a human.
  • the subject is diagnosed with a chronic viral infection.
  • administration is under conditions such that the viral infection is no longer detected.
  • the subject is diagnosed with a RNA virus, DNA virus, or retroviruses.
  • the subject is diagnosed with a virus that is a double stranded DNA virus, sense single stranded DNA virus, double stranded RNA virus, sense single stranded RNA virus, antisense single stranded RNA virus, sense single stranded RNA retrovirus or a double stranded DNA retrovirus.
  • the disclosure relates to uses of compounds disclosed herein in the production or manufacture of a medicament for the treatment or prevention of an infectious disease, viral infection, or cancer.
  • the disclosure relates to derivatives of compounds disclosed herein or any of the formula.
  • Embodiments of the present disclosure will employ, unless otherwise indicated, techniques of medicine, organic chemistry, biochemistry, molecular biology, pharmacology, and the like, which are within the skill of the art. Such techniques are explained fully in the literature.
  • a pharmaceutical agent which may be in the form of a salt or prodrug, is administered in methods disclosed herein that is specified by a weight. This refers to the weight of the recited compound. If in the form of a salt or prodrug, then the weight is the molar equivalent of the corresponding salt or prodrug. It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. In this specification and in the claims that follow, reference will be made to a number of terms that shall be defined to have the following meanings unless a contrary intention is apparent.
  • the joined molecules may bond to oxygen or directly to the phosphorus atoms.
  • the term is intended to include, but are not limited to phosphates, in which the phosphorus is typically bonded to four oxygens and phosphonates, in which the phosphorus is typically bonded to one carbon and three oxygens.
  • a “polyphosphate” generally refers to phosphates linked together by at least one phosphorus-oxygen-phosphorus (P-O-P) bond.
  • the terms “prevent” and “preventing” include the prevention of the recurrence, spread or onset. It is not intended that the present disclosure be limited to complete prevention. In some embodiments, the onset is delayed, or the severity of the disease is reduced.
  • alkyl means a straight or branched chain saturated hydrocarbon moieties such as those containing from 1 to 10 carbon atoms.
  • a “higher alkyl” refers to saturated hydrocarbon having 11 or more carbon atoms.
  • a “C 6 -C 16 ” refers to an alkyl containing 6 to 16 carbon atoms.
  • a “C 6 -C 22 ” refers to an alkyl containing 6 to 22 carbon atoms.
  • Representative saturated straight chain alkyls include methyl, ethyl, n- propyl, n-butyl, n-pentyl, n-hexyl, n-septyl, n-octyl, n-nonyl, and the like; while saturated branched alkyls include isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, and the like.
  • alkenyl refers to unsaturated, straight or branched hydrocarbon moieties containing a double bond.
  • C 2 -C 24 (e.g., C 2 -C 22 , C 2 -C 20 , C 2 -C 18 , C 2 -C 16 , C 2 -C 14 , C 2 -C 12 , C 2 -C 10 , C 2 -C 8 , C 2 -C 6 , or C 2 -C 4 ) alkenyl groups are intended.
  • Alkenyl groups may contain more than one unsaturated bond.
  • alkynyl represents straight or branched hydrocarbon moieties containing a triple bond.
  • C 2 -C 24 (e.g., C 2 -C 24 , C 2 -C 20 , C 2 -C 18 , C 2 -C 16 , C 2 -C 14 , C 2 -C 12 , C 2 -C 10 , C 2 -C 8 , C 2 -C 6 , or C 2 -C 4 ) alkynyl groups are intended.
  • Alkynyl groups may contain more than one unsaturated bond.
  • Examples include C2-C6- alkynyl, such as ethynyl, 1-propynyl, 2-propynyl (or propargyl), 1-butynyl, 2-butynyl, 3- butynyl, 1-methyl-2-propynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 3-methyl-1- butynyl, 1-methyl-2-butynyl, 1-methyl-3-butynyl, 2-methyl-3-butynyl, 1,1-dimethyl-2- propynyl, 1-ethyl-2-propynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 3- methyl-1-pentynyl, 4-methyl-1-pentynyl, 1-methyl-2-pentynyl, 4-methyl-2-penty
  • Heterocarbocycles or heterocarbocyclyl groups are carbocycles which contain from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur which can be saturated or unsaturated (but not aromatic), monocyclic or polycyclic, and wherein the nitrogen and sulfur heteroatoms can be optionally oxidized, and the nitrogen heteroatom can be optionally quaternized.
  • heteroaryl or “heteroaromatic” refers an aromatic heterocarbocycle having 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, and containing at least 1 carbon atom, including both mono- and polycyclic ring systems.
  • Polycyclic ring systems can, but are not required to, contain one or more non-aromatic rings, as long as one of the rings is aromatic.
  • heteroaryls are furyl, benzofuranyl, thiophenyl, benzothiophenyl, pyrrolyl, indolyl, isoindolyl, azaindolyl, pyridyl, quinolinyl, isoquinolinyl, oxazolyl, isooxazolyl, benzoxazolyl, pyrazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, and quinazolinyl. It is contemplated that the use of the term "heteroaryl” includes N-alkylated derivatives such as a 1-methylimidazol- 5-yl substituent.
  • heterocycle or “heterocyclyl” refers to mono- and polycyclic ring systems having 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, and containing at least 1 carbon atom.
  • the mono- and polycyclic ring systems can be aromatic, non-aromatic or mixtures of aromatic and non-aromatic rings.
  • Heterocycle includes heterocarbocycles, heteroaryls, and the like.
  • Alkoxy refers to an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge.
  • alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n- pentoxy, and s-pentoxy.
  • Preferred alkoxy groups are methoxy, ethoxy, n-propoxy, i- propoxy, n-butoxy, s-butoxy, t-butoxy.
  • Alkylamino refers an alkyl group as defined above with the indicated number of carbon atoms attached through an amino bridge.
  • An example of an alkylamino is methylamino, (i.e., -NH-CH 3 ).
  • cycloalkyl and cycloalkenyl refer to mono-, bi-, or tri homocyclic ring groups of 3 to 15 carbon atoms which are, respectively, fully saturated and partially unsaturated.
  • cycloalkenyl includes bi- and tricyclic ring systems that are not aromatic as a whole, but contain aromatic portions (e.g., fluorene, tetrahydronapthalene, dihydroindene, and the like).
  • the rings of multi-ring cycloalkyl groups can be either fused, bridged and/or joined through one or more spiro unions.
  • substituted cycloalkyl and “substituted cycloalkenyl” refer, respectively, to cycloalkyl and cycloalkenyl groups substituted with one or more groups, preferably selected from aryl, substituted aryl, heterocyclo, substituted heterocyclo, carbocyclo, substituted carbocyclo, halo, hydroxy, alkoxy (optionally substituted), aryloxy (optionally substituted), alkylester (optionally substituted), arylester (optionally substituted), alkanoyl (optionally substituted), aryol (optionally substituted), cyano, nitro, amino, substituted amino, amido, lactam, urea, urethane, sulfonyl, and the like.
  • halogen and “halo” refer to fluorine, chlorine, bromine, and iodine.
  • Ra and Rb in this context can be the same or different and independently hydrogen, halogen hydroxyl, alkyl, alkoxy, alkyl, amino, alkylamino, dialkylamino, carbocyclyl, carbocycloalkyl, heterocarbocyclyl, heterocarbocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl.
  • salts refer to derivatives of the disclosed compounds where the parent compound is modified making acid or base salts thereof.
  • salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, alkylamines, or dialkylamines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the salts are conventional nontoxic pharmaceutically acceptable salts including the quaternary ammonium salts of the parent compound formed, and non-toxic inorganic or organic acids.
  • Preferred salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2- acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
  • organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic
  • prodrug refers to an agent that is converted into a biologically active form in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent compound. They may, for instance, be bioavailable by oral administration whereas the parent compound is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. A prodrug may be converted into the parent drug by various mechanisms, including enzymatic processes and metabolic hydrolysis.
  • the term “derivative” refers to a structurally similar compound that retains sufficient functional attributes of the identified analogue.
  • the derivative may be structurally similar because it is lacking one or more atoms, substituted with one or more substituents, a salt, in different hydration/oxidation states, e.g., substituting a single or double bond, substituting a hydroxy group for a ketone, or because one or more atoms within the molecule are switched, such as, but not limited to, replacing an oxygen atom with a sulfur or nitrogen atom or replacing an amino group with a hydroxyl group or vice versa.
  • Replacing a carbon with nitrogen in an aromatic ring is a contemplated derivative.
  • the derivative may be a prodrug.
  • Derivatives may be prepared by any variety of synthetic methods or appropriate adaptations presented in the chemical literature or as in synthetic or organic chemistry text books, such as those provide in March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, Wiley, 6th Edition (2007) Michael B. Smith or Domino Reactions in Organic Synthesis, Wiley (2006) Lutz F. Tietze hereby incorporated by reference.
  • tautomer refers to each of two or more constitutional isomers of a compound which exist together in equilibrium and readily interconvert by rearrangement of a pi bond and an atom or group.
  • a common example are keto-enol tautomers. These form when a hydrogen atom on the carbon atom attached to the carbonyl carbon moves to the oxygen atom of the carbonyl group. As this occurs a bond from the carbon-oxygen double bond of the carbonyl group moves and forms a double between what was the carbonyl carbon and the carbon where the hydrogen atom came from.
  • Another common example of tautomers are amino-imino tautomers.
  • Keto-enol and amino-imino tautomers are common in modified and unmodified nucleobases found in DNA and RNA.
  • Compounds disclosed herein can exist as tautomers and the specific disclosure of one tautomer is meant to expressly include the other tautomer of the compound.
  • the disclosure relates to nucleosides conjugated to a phosphorus moiety or pharmaceutically acceptable salts thereof.
  • the disclosure relates to tautomers of the natural and unnatural nucleobase of compounds disclosed herein.
  • the disclosure relates to a compound of Formula I,
  • U is O, S, NH, NR 7 , CH 2 , CHF, CF 2 , CCH 2 , or CCF 2 ;
  • Q is a natural or unnatural nucleobase
  • R 1 is selected from H, substituted esters, optionally substituted branched esters, optionally substituted carbonates, optionally substituted carbamates, optionally substituted thioesters, optionally substituted branched thioesters, optionally substituted thiocarbonates, optionally substituted S- thiocarbonate, optionally substituted dithiocarbonates, optionally substituted thiocarbamates, optionally substituted oxymethoxycarbonyl, optionally substituted oxymethoxythiocarbonyl, optionally substituted oxymethylcarbonyl, optionally substituted oxymethylthiocarbonyl, L-amino acid esters, D-amino acid esters, N-substituted L-amino acid esters, N,N-disubstituted L-amino acid esters, N-substituted D-amino acid esters, N,N- disubstituted D-amino acid esters, optionally substituted sulfeny
  • Y 1 is OH, OY 3 , or BH 3 M + ;
  • Y 2 is OH or BH 3 M + ;
  • R 2 and R 2 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 3 and R 3 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 5 is hydrogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, allenyl, or lipid, wherein R 5 is optionally substituted with one or more, the same or different, R 10 ;
  • R 6 , R 6 , R 6 , and R 6 are each independently selected from hydrogen, deuterium, hydroxyl, amino, azido, thiol, acyl, formyl, halogen, nitro, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio,
  • R 7 and R 7 are each independently selected from hydrogen, deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalky
  • R 8 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 9 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 7 , R 7 , R 8 , and R 9 can form a ring with the a-carbon they are attached to and the amino group attached to the a-carbon, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 7 and R 7 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 8 and R 9 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 10 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 11 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, heterocyclylthio, cycloalkylthio, cycloalkenylthio, allenyl, sulfinyl, sulfamoyl, sulfonyl, lipid, nitro, or carbonyl;
  • the lipid is a sphingolipid of the formula: wherein,
  • R 14 of the sphingolipid is a saturated or unsaturated alkyl chain of greater than 6 and less than 22 carbons optionally substituted with one or more halogen or hydroxy or a structure of the following formula: wherein n is 8 to 14 or less than or equal to 8 to less than or equal to 14, o is 9 to 15 or less than or equal to 9 to less than or equal to 15, the total or m and n is 8 to 14 or less than or equal to 8 to less than or equal to 14, the total of m and o is 9 to 15 or less than or equal to 9 to less than or equal to 15; or wherein n is 4 to 10 or less than or equal to 4 to less than or equal to 10, o is 5 to 11 or less than or equal to 5 to less than or equal to 11, the total of m and n is 4 to 10 or less than or equal to 4 to less than or equal to 10, and the total of m and o is 5 to 11 or less than or equal to 5 to less than or equal to 11; or wherein n is 6 to
  • R 12 of the sphingolipid is H, methyl, ethyl, propyl, n-butyl, isopropyl, 2-butyl, l-ethylpropyl,l-propylbutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, benzyl, or phenyl.
  • the sphingolipid is a sphingolipid of the formula: wherein,
  • R 2 , R 2 , R 3 , R 3 are hydrogen, hydroxyl, amino, fluoro, chloro, cyano, methyl, fluoromethyl, methoxy, vinyl, ethynyl, and chloroethynyl.
  • R 7 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4- septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N- dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • Y 3 is aryl, heteroaryl, or heterocyclyl, wherein Y 3 is optionally substituted with one or more, the same or different, R 10 ;
  • R 2 , R 2 , R 3 , R 3 are each independently selected from hydrogen, deuterium, alkyl, alkenyl, alkynyl, allenyl, alkoxy, hydroxy, thiol, amino, azido, formyl, acyl, cyano, halogen, aryl, heteroaryl, heterocyclyl, carbocyclyl, heterocarbocyclyl, sulfmyl, sulfamoyl, or sulfonyl, wherein R 2 , R 2 , R 3 , R 3 are optionally substituted with one or more, the same or different, R 10 ;
  • R 4 is hydrogen or deuterium
  • R 9 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 11 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalkenylthio, allenyl, sulfinyl, sulfamoyl, sulfonyl,
  • R 1 is hydroge . ormula II, X is CH 2 .
  • U is O.
  • W is CR’.
  • Z is CR’.
  • R’ is H, F, Cl, OH, methyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, vinyl, ethynyl, formyl.
  • R’’ is H, F, Cl, OH, methyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, vinyl, ethynyl, formyl.
  • R 2 , R 2’ , R 3 , R 3’ are hydrogen, hydroxyl, amino, fluoro, chloro, cyano, methyl, fluoromethyl, methoxy, vinyl, ethynyl, and chloroethynyl.
  • R 6 is hydrogen, hydroxyl, fluoro, chloro, amino, lipid, methyl, methoxy, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert- butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N-dimethylamino, N,N- diethylamino, and N,N-dipropylamino.
  • R 9 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4- septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N- dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • the disclosure relates to a compound of Formula III, or a pharmaceutical or physiological salt thereof, wherein
  • W is N or CR’
  • Z is N or CR
  • R’ is hydrogen, deuterium, halogen, hydroxyl, amino, thiol, alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, heterocarbocyclyl, cycloalkyl, heterocyclyl, or acyl, wherein R’ is optionally substituted with one or more, the same or different, R 10 ;
  • R” is hydrogen, deuterium, halogen, hydroxyl, amino, thiol, alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, heterocarbocyclyl, cycloalkyl, heterocyclyl, or acyl, wherein R” is optionally substituted with one or more, the same or different, R 10 ;
  • R 1 is selected from H
  • esters optionally substituted branched esters, optionally substituted carbonates, optionally substituted carbamates, optionally substituted thioesters, optionally substituted branched thioesters, optionally substituted thiocarbonates, optionally substituted S-thiocarbonate, optionally substituted dithiocarbonates, optionally substituted thiocarbamates, optionally substituted oxymethoxy carbonyl, optionally substituted oxymethoxythiocarbonyl, optionally substituted oxymethylcarbonyl, optionally substituted oxymethylthiocarbonyl, L- amino acid esters, D-amino acid esters, N-substituted L-amino acid esters, N,N- disubstituted L-amino acid esters, N-substituted D-amino acid esters, N,N-disubstituted D- amino acid esters, optionally substituted sulfenyl, optionally substituted imidate, optionally substituted hydr
  • Y 2 is OH or BH 3 M + ;
  • R 2 and R 2 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 3 and R 3 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 4 is hydrogen or deuterium
  • R 5 is hydrogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, allenyl, or lipid, wherein R 5 is optionally substituted with one or more, the same or different, R 10 ;
  • R 6 , R 6 , R 6 , and R 6 are each independently selected from hydrogen, deuterium, hydroxyl, amino, azido, thiol, acyl, formyl, halogen, nitro, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio,
  • R 8 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 9 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 7 , R 7 , R 8 , and R 9 can form a ring with the a-carbon they are attached to and the amino group attached to the a-carbon, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • Lipid is a C 11 -C 22 higher alkyl, C 11 -C 22 higher alkoxy, polyethylene glycol, or aryl substituted with an alkyl group, or a lipid as described herein.
  • R 1 is hydrogen
  • W is CR
  • Z is CR”.
  • R is H, F, Cl, OH, methyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, vinyl, ethynyl, formyl.
  • R 2 , R 2 , R 3 , R 3 are hydrogen, hydroxyl, amino, fluoro, chloro, cyano, methyl, fluoromethyl, methoxy, vinyl, ethynyl, and chloroethynyl.
  • R 6 is hydrogen, hydroxyl, fluoro, chloro, amino, lipid, methyl, methoxy, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert- butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N-dimethylamino, N,N- diethylamino, and N,N-dipropylamino.
  • R 7 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4- septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N- dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 8 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4- septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N- dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 9 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4- septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N- dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • the disclosure relates to a compound of Formula IV, or a pharmaceutical or physiological salt thereof, wherein
  • W is N or CR’
  • Z is N or CR
  • R’ is hydrogen, deuterium, halogen, hydroxyl, amino, thiol, alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, heterocarbocyclyl, cycloalkyl, heterocyclyl, or acyl, wherein R’ is optionally substituted with one or more, the same or different, R 10 ;
  • R is hydrogen, deuterium, halogen, hydroxyl, amino, thiol, alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, heterocarbocyclyl, cycloalkyl, heterocyclyl, or acyl, wherein R” is optionally substituted with one or more, the same or different, R 10 ;
  • R 2 , R 2 , R 3 , R 3 are each independently selected from hydrogen, deuterium, alkyl, alkenyl, alkynyl, allenyl, alkoxy, hydroxy, thiol, amino, azido, formyl, acyl, cyano, halogen, aryl, heteroaryl, heterocyclyl, carbocyclyl, heterocarbocyclyl, sulfmyl, sulfamoyl, or sulfonyl, wherein R 2 , R 2 , R 3 , R 3 are optionally substituted with
  • R 2 and R 2 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 3 and R 3 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 4 is hydrogen or deuterium
  • R 10 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 11 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • Lipid is a C 11 -C 22 higher alkyl, C 11 -C 22 higher alkoxy, polyethylene glycol, or aryl substituted with an alkyl group, or a lipid as described herein.
  • W is CR
  • Z is CR”.
  • R’ is H, F, Cl, OH, methyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, vinyl, ethynyl, formyl.
  • R” is H, F, Cl, OH, methyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, vinyl, ethynyl, formyl.
  • R 2 , R 2 , R 3 , R 3 are hydrogen, hydroxyl, amino, fluoro, chloro, cyano, methyl, fluoromethyl, methoxy, vinyl, ethynyl, and chloroethynyl.
  • the disclosure relates to a compound of Formula V, or a pharmaceutical or physiological salt thereof, wherein
  • W is N or CR’
  • Z is N or CR
  • R’ is hydrogen, deuterium, halogen, hydroxyl, amino, thiol, alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, heterocarbocyclyl, cycloalkyl, heterocyclyl, or acyl, wherein R’ is optionally substituted with one or more, the same or different, R 10 ;
  • R is hydrogen, deuterium, halogen, hydroxyl, amino, thiol, alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, heterocarbocyclyl, cycloalkyl, heterocyclyl, or acyl, wherein R” is optionally substituted with one or more, the same or different, R 10 ;
  • R 2 and R 2 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 3 and R 3 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 4 is hydrogen or deuterium
  • R 10 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 11 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • Lipid is a C 11 -C 22 higher alkyl, C 11 -C 22 higher alkoxy, polyethylene glycol, or aryl substituted with an alkyl group, or a lipid as described herein.
  • W is CR’.
  • R’ is H, F, Cl, OH, methyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, vinyl, ethynyl, formyl.
  • R is H, F, Cl, OH, methyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, vinyl, ethynyl, formyl.
  • R 2 , R 2 , R 3 , R 3 are hydrogen, hydroxyl, amino, fluoro, chloro, cyano, methyl, fluoromethyl, methoxy, vinyl, ethynyl, and chloroethynyl.
  • the disclosure relates to a compound of Formula VI,
  • W is N or CR’;
  • Z is N or CR”;
  • R’ is hydrogen, deuterium, halogen, hydroxyl, amino, thiol, alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, heterocarbocyclyl, cycloalkyl, heterocyclyl, or acyl, wherein R’ is optionally substituted with one or more, the same or different, R 10 ;
  • R 2 , R 2 , R 3 , R 3 are each independently selected from hydrogen, deuterium, alkyl, alkenyl, alkynyl, allenyl, alkoxy, hydroxy, thiol, amino, azido, formyl, acyl, cyano, halogen, aryl, heteroaryl, heterocyclyl, carbocyclyl, heterocarbocyclyl, sulfmyl, sulfamoyl, or sulfonyl, wherein R 2 , R 2 , R 3 , R 3 are optionally substituted with one or more, the same or different, R 10 ;
  • R 2 and R 2 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 3 and R 3 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 4 is hydrogen or deuterium
  • R 6 , R 6 , R 6 , and R 6 are each independently selected from hydrogen, deuterium, hydroxyl, amino, azido, thiol, acyl, formyl, halogen, nitro, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio,
  • Lipid is a C 11 -C 22 higher alkyl, C 11 -C 22 higher alkoxy, polyethylene glycol, or aryl substituted with an alkyl group, or a lipid as described herein.
  • W is CR’
  • Z is CR”.
  • R’ is H, F, Cl, OH, methyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, vinyl, ethynyl, formyl.
  • R is H, F, Cl, OH, methyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, vinyl, ethynyl, formyl.
  • R 2 , R 2 , R 3 , R 3 are hydrogen, hydroxyl, amino, fluoro, chloro, cyano, methyl, fluoromethyl, methoxy, vinyl, ethynyl, and chloroethynyl.
  • R 6 , R 6’ , R 6” , and R 6 are all hydrogen. In exemplified embodiments of Formula VI, R 6 , R 6 , and R 6 are hydrogen and R 6 is methyl.
  • R 6 , R 6’ , and R 6 are hydrogen and R 6 is methoxy. In exemplified embodiments of Formula VI, R 6 , R 6 , and R 6 are hydrogen and R 6 is methyl.
  • R 6 , R 6” , and R 6 are hydrogen and R 6 is methoxy.
  • R 6 , R 6 , and R 6 are hydrogen and R 6 is fluoro.
  • R 6 , R 6 , and R 6 are hydrogen and R 6 I tert-butyl.
  • R 6 , R 6” , and R 6 are hydrogen and R 6 is chloro.
  • R 6 and R 6 are hydrogen and R 6 and
  • R 1 is selected from H, esters, optionally substituted branched esters, optionally substituted carbonates, optionally substituted carbamates, optionally substituted thioesters, optionally substituted branched thioesters, optionally substituted thiocarbonates, optionally substituted S-thiocarbonate, optionally substituted dithiocarbonates, optionally substituted thiocarbamates, optionally substituted oxymethoxy carbonyl, optionally substituted oxymethoxythiocarbonyl, optionally substituted oxymethylcarbonyl, optionally substituted oxymethylthiocarbonyl, L- amino acid esters, D-amino acid esters, N-substituted L-amino acid esters, N,N- disubstituted L-amino acid esters, N-substituted D-amino acid esters, N,N-disubstituted D- amino acid esters, optionally substituted sulfenyl, optionally substituted imi
  • R 3 and R 3 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 7 , R 7 , R 8 , and R 9 can form a ring with the a-carbon they are attached to and the amino group attached to the a-carbon, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 7 and R 7 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 8 and R 9 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 11 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • W is CR
  • the disclosure relates to a compound of Formula X, or a pharmaceutical or physiological salt thereof, wherein
  • R 2 , R 2 , R 3 , R 3 are each independently selected from hydrogen, deuterium, alkyl, alkenyl, alkynyl, allenyl, alkoxy, hydroxy, thiol, amino, azido, formyl, acyl, cyano, halogen, aryl, heteroaryl, heterocyclyl, carbocyclyl, heterocarbocyclyl, sulfmyl, sulfamoyl, or sulfonyl, wherein R 2 , R 2 , R 3 , R 3 are optionally substituted with one or more, the same or different, R 10 ; R 2 and R 2 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 3 and R 3 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R is H, F, Cl, OH, methyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, vinyl, ethynyl, formyl.
  • the disclosure relates to a compound of Formula XI, or a pharmaceutical or physiological salt thereof, wherein W is N or CR’;
  • Lipid is a C 11 -C 22 higher alkyl, C 11 -C 22 higher alkoxy, polyethylene glycol, or aryl substituted with an alkyl group, or a lipid as described herein.
  • W is CR
  • the disclosure relates to a compound of Formula XII, or a pharmaceutical or physiological salt thereof, wherein W is N or CR’; Z is N or CR”; R’ is hydrogen, deuterium, halogen, hydroxyl, amino, thiol, alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, heterocarbocyclyl, cycloalkyl, heterocyclyl, or acyl, wherein R’ is optionally substituted with one or more, the same or different, R 10 ;
  • R 2 and R 2 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R is H, F, Cl, OH, methyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, vinyl, ethynyl, formyl.
  • R 2 , R 2 , R 3 , R 3 are hydrogen, hydroxyl, amino, fluoro, chloro, cyano, methyl, fluoromethyl, methoxy, vinyl, ethynyl, and chloroethynyl.
  • R 6 , R 6 , R 6 , and R 6 are all hydrogen.
  • R 6 , R 6 , and R 6 are hydrogen and R 6 is methyl.
  • R 6 , R 6’ , and R 6 are hydrogen and R 6 is methoxy.
  • R 6 , R 6” , and R 6 are hydrogen and R 6 is methoxy.
  • R 6 , R 6 , and R 6 are hydrogen and R 6 is fluoro.
  • R 6 , R 6” , and R 6 are hydrogen and R 6 I tert-butyl.
  • R 6 , R 6 , and R 6 are hydrogen and R 6 is chloro. In exemplified embodiments of Formula XII, R 6 and R 6 are hydrogen and R 6 and R 6 are methyl.
  • R 6’ , R 6 , and R 6 are hydrogen and R 6 is fluoro.
  • R 6 is hydrogen, R 6 and R 6 are tert- butyl, and R 6 is fluoro.
  • the disclosure relates to a compound of Formula XIII, or a pharmaceutical or physiological salt thereof, wherein
  • X is CH 2, CHMe, CMe 2 , CHF, CF 2 , or CD 2 ;
  • U is S, NH, NRv, CH 2 , CHF, CF 2 , CCH 2 , or CCF 2 ;
  • W is N or CR’
  • Z is N or CR”;
  • R’ is hydrogen, deuterium, halogen, hydroxyl, amino, thiol, alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, heterocarbocyclyl, cycloalkyl, heterocyclyl, or acyl, wherein R’ is optionally substituted with one or more, the same or different, R 10 ;
  • R is hydrogen, deuterium, halogen, hydroxyl, amino, thiol, alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, heterocarbocyclyl, cycloalkyl, heterocyclyl, or acyl, wherein R” is optionally substituted with one or more, the same or different, R 10 ;
  • esters optionally substituted branched esters, optionally substituted carbonates, optionally substituted carbamates, optionally substituted thioesters, optionally substituted branched thioesters, optionally substituted thiocarbonates, optionally substituted S-thiocarbonate, optionally substituted dithiocarbonates, optionally substituted thiocarbamates, optionally substituted oxymethoxy carbonyl, optionally substituted oxymethoxythiocarbonyl, optionally substituted oxymethylcarbonyl, optionally substituted oxymethylthiocarbonyl, L- amino acid esters, D-amino acid esters, N-substituted L-amino acid esters, N,N- disubstituted L-amino acid esters, N-substituted D-amino acid esters, N,N-disubstituted D- amino acid esters, optionally substituted sulfenyl, optionally substituted imidate, optionally substituted hydr
  • Y is O or S
  • Y 1 is OH, OY 3 , or BH 3 M + ;
  • Y 2 is OH or BH 3 M + ;
  • Y 3 is aryl, heteroaryl, or heterocyclyl, wherein Y 3 is optionally substituted with one or more, the same or different, R 10 ;
  • R 2 and R 2 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 3 and R 3 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 5 is hydrogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, allenyl, or lipid, wherein R 5 is optionally substituted with one or more, the same or different, R 10 ;
  • R 6 , R 6 , R 6 , and R 6 are each independently selected from hydrogen, deuterium, hydroxyl, amino, azido, thiol, acyl, formyl, halogen, nitro, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio,
  • R 7 and R 7 are each independently selected from hydrogen, deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalky
  • R 8 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 9 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 7 , R 7 , R 8 , and R 9 can form a ring with the a-carbon they are attached to and the amino group attached to the a-carbon, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 7 and R 7 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 8 and R 9 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 10 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 11 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • Lipid is a C 11 -C 22 higher alkyl, C 11 -C 22 higher alkoxy, polyethylene glycol, or aryl substituted with an alkyl group, or a lipid as described herein.
  • R 1 is hydrogen
  • X is CH 2 .
  • W is CR
  • Z is CR”.
  • R’ is H, F, Cl, OH, methyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, vinyl, ethynyl, formyl.
  • R is H, F, Cl, OH, methyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, vinyl, ethynyl, formyl.
  • R 2 , R 2 , R 3 , R 3 are hydrogen, hydroxyl, amino, fluoro, chloro, cyano, methyl, fluoromethyl, methoxy, vinyl, ethynyl, and chloroethynyl.
  • R 5 is lipid, methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 6 is hydrogen, hydroxyl, fluoro, chloro, amino, lipid, methyl, methoxy, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert- butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N-dimethylamino, N,N- diethylamino, and N,N-dipropylamino.
  • R 7 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4- septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N- dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 8 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4- septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N- dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 9 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4- septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N- dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • the disclosure relates to a compound of Formula XIV, or a pharmaceutical or physiological salt thereof, wherein X is CHMe, CMe 2 , CHF, CF 2 , or CD 2 ;
  • Z is N or CR
  • Y is O or S
  • R 9 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 7 , R 7 , R 8 , and R 9 can form a ring with the a-carbon they are attached to and the amino group attached to the a-carbon, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 7 and R 7 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 8 and R 9 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 10 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 11 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • Lipid is a C 11 -C 22 higher alkyl, C 11 -C 22 higher alkoxy, polyethylene glycol, or aryl substituted with an alkyl group, or a lipid as described herein.
  • R is hydrogen
  • W is CR
  • Z is CR”.
  • R’ is H, F, Cl, OH, methyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, vinyl, ethynyl, formyl.
  • R is H, F, Cl, OH, methyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, vinyl, ethynyl, formyl.
  • R 2 , R 2 , R 3 , R 3 are hydrogen, hydroxyl, amino, fluoro, chloro, cyano, methyl, fluoromethyl, methoxy, vinyl, ethynyl, and chloroethynyl.
  • R 5 is lipid, methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 6 is hydrogen, hydroxyl, fluoro, chloro, amino, lipid, methyl, methoxy, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert- butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N-dimethylamino, N,N- diethylamino, and N,N-dipropylamino.
  • R 7 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4- septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N- dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 8 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4- septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N- dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 9 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4- septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N- dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • the disclosure relates to a compound of Formula XV, or a pharmaceutical or physiological salt thereof, wherein W is N or CR’;
  • Z is N or CR
  • esters optionally substituted branched esters, optionally substituted carbonates, optionally substituted carbamates, optionally substituted thioesters, optionally substituted branched thioesters, optionally substituted thiocarbonates, optionally substituted S-thiocarbonate, optionally substituted dithiocarbonates, optionally substituted thiocarbamates, optionally substituted oxymethoxy carbonyl, optionally substituted oxymethoxythiocarbonyl, optionally substituted oxymethylcarbonyl, optionally substituted oxymethylthiocarbonyl, L- amino acid esters, D-amino acid esters, N-substituted L-amino acid esters, N,N- disubstituted L-amino acid esters, N-substituted D-amino acid esters, N,N-disubstituted D- amino acid esters, optionally substituted sulfenyl, optionally substituted imidate, optionally substituted hydr
  • Y 2 is OH or BH 3 M + ;
  • Y 3 is aryl, heteroaryl, or heterocyclyl, wherein Y 3 is optionally substituted with one or more, the same or different, R 10 ;
  • R 2 is selected from deuterium, alkyl, alkenyl, alkynyl, allenyl, alkoxy, thiol, amino, azido, formyl, acyl, cyano, halogen, aryl, heteroaryl, heterocyclyl, carbocyclyl, heterocarbocyclyl, sulfmyl, sulfamoyl, or sulfonyl, wherein R 2 is optionally substituted with one or more, the same or different, R 10 ;
  • R 3 is selected from hydrogen, deuterium, alkyl, alkenyl, alkynyl, allenyl, alkoxy, hydroxy, thiol, amino, azido, formyl, acyl, cyano, halogen, aryl, heteroaryl, heterocyclyl, carbocyclyl, heterocarbocyclyl, sulfmyl, sulfamoyl, or sulfonyl, wherein R 3 is optionally substituted with one or more, the same or different, R 10 ;
  • R 3 is selected fromhydrogen, deuterium, alkyl, alkenyl, alkynyl, allenyl, alkoxy, hydroxy, thiol, amino, azido, formyl, acyl, cyano, halogen, aryl, heteroaryl, heterocyclyl, carbocyclyl, heterocarbocyclyl, sulfmyl, sulfamoyl, or sulfonyl, wherein R 3 is optionally substituted with one or more, the same or different, R 10 ;
  • R 2 and R 2 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 3 and R 3 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 5 is hydrogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, allenyl, or lipid, wherein R 5 is optionally substituted with one or more, the same or different, R 10 ;
  • R 6 , R 6 , R 6 , and R 6 are each independently selected from hydrogen, deuterium, hydroxyl, amino, azido, thiol, acyl, formyl, halogen, nitro, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio,
  • R 7 and R 7 are each independently selected from hydrogen, deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalky
  • R 8 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 9 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 7 , R 7 , R 8 , and R 9 can form a ring with the a-carbon they are attached to and the amino group attached to the a-carbon, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 8 and R 9 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 10 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 11 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • Lipid is a C 11 -C 22 higher alkyl, C 11 -C 22 higher alkoxy, polyethylene glycol, or aryl substituted with an alkyl group, or a lipid as described herein.
  • R 1 is hydrogen
  • W is CR’.
  • Z is CR”.
  • R’ is H, F, Cl, OH, methyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, vinyl, ethynyl, formyl.
  • R 9 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 7 , R 7 , R 8 , and R 9 can form a ring with the a-carbon they are attached to and the amino group attached to the a-carbon, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 7 and R 7 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 10 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 11 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • Lipid is a C 11 -C 22 higher alkyl, C 11 -C 22 higher alkoxy, polyethylene glycol, or aryl substituted with an alkyl group, or a lipid as described herein.
  • R 1 is hydrogen
  • W is CR’
  • Z is CR”.
  • R’ is H, F, Cl, OH, methyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, vinyl, ethynyl, formyl.
  • R is H, F, Cl, OH, methyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, vinyl, ethynyl, formyl.
  • R 5 is lipid, methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R’ is deuterium, halogen, hydroxyl, amino, thiol, alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, heterocarbocyclyl, cycloalkyl, heterocyclyl, or acyl, wherein R’ is optionally substituted with one or more, the same or different, R 10 ;
  • Y 1 is OH, OY 3 , or BH 3 M + ;
  • Y 2 is OH or BH 3 M + ;
  • Y 3 is aryl, heteroaryl, or heterocyclyl, wherein Y 3 is optionally substituted with one or more, the same or different, R 10 ;
  • R 3 and R 3 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 5 is hydrogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, allenyl, or lipid, wherein R 5 is optionally substituted with one or more, the same or different, R 10 ;
  • R 7 and R 7 are each independently selected from hydrogen, deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalky
  • R 9 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 7 , R 7 , R 8 , and R 9 can form a ring with the a-carbon they are attached to and the amino group attached to the a-carbon, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 7 and R 7 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 10 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 5 is lipid, methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 7 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 8 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 9 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • the disclosure relates to a compound of Formula XVIII, or a pharmaceutical or physiological salt thereof, wherein Z is N or CR”; R” is deuterium, halogen, hydroxyl, amino, thiol, alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, heterocarbocyclyl, cycloalkyl, heterocyclyl, or acyl, wherein R” is optionally substituted with one or more, the same or different, R 10 ;
  • R 1 is selected from H, S , p y ed esters, optionally substituted branched esters, optionally substituted carbonates, optionally substituted carbamates, optionally substituted thioesters, optionally substituted branched thioesters, optionally substituted thiocarbonates, optionally substituted S-thiocarbonate, optionally substituted dithiocarbonates, optionally substituted thiocarbamates, optionally substituted oxymethoxy carbonyl, optionally substituted oxymethoxythiocarbonyl, optionally substituted oxymethylcarbonyl, optionally substituted oxymethylthiocarbonyl, L- amino acid esters, D-amino acid esters, N-substituted L-amino acid esters, N,N- disubstituted L-amino acid esters, N-substituted D-amino acid esters, N,N-disubstituted D- amino acid esters, optionally substituted sul
  • Y 1 is OH, OY 3 , or BH 3 M + ;
  • Y 2 is OH or BH 3 M + ;
  • R 2 is selected from deuterium, alkyl, alkenyl, alkynyl, allenyl, alkoxy, thiol, amino, azido, formyl, acyl, cyano, halogen, aryl, heteroaryl, heterocyclyl, carbocyclyl, heterocarbocyclyl, sulfmyl, sulfamoyl, or sulfonyl, wherein R 2 is optionally substituted with one or more, the same or different, R 10 ;
  • R 3 and R 3 are each independently selected from hydrogen, deuterium, alkyl, alkenyl, alkynyl, allenyl, alkoxy, hydroxy, thiol, amino, azido, formyl, acyl, cyano, halogen, aryl, heteroaryl, heterocyclyl, carbocyclyl, heterocarbocyclyl, sulfmyl, sulfamoyl, or sulfonyl, wherein R 3 and R 3 are optionally substituted with one or more, the same or different, R 10 ;
  • R 3 and R 3 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 7 and R 7 are each independently selected from hydrogen, deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalky
  • R 8 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 9 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 7 and R 7 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 8 and R 9 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 10 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 11 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • Lipid is a C 11 -C 22 higher alkyl, C 11 -C 22 higher alkoxy, polyethylene glycol, or aryl substituted with an alkyl group, or a lipid as described herein.
  • R 5 is lipid, methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 7 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 8 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 9 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R’ is hydrogen, deuterium, halogen, hydroxyl, amino, thiol, alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, heterocarbocyclyl, cycloalkyl, heterocyclyl, or acyl, wherein R’ is optionally substituted with one or more, the same or different, R 10 ;
  • R is deuterium, halogen, hydroxyl, amino, thiol, alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, heterocarbocyclyl, cycloalkyl, heterocyclyl, or acyl, wherein R” is optionally substituted with one or more, the same or different, R 10 ;
  • R 1 is selected from H
  • Y is O or S
  • Y 1 is OH, OY 3 , or BH 3 M + ;
  • Y 2 is OH or BH 3 M + ;
  • Y 3 is aryl, heteroaryl, or heterocyclyl, wherein Y 3 is optionally substituted with one or more, the same or different, R 10 ;
  • R 3 is selected fromhydrogen, deuterium, alkyl, alkenyl, alkynyl, allenyl, alkoxy, hydroxy, thiol, amino, azido, formyl, acyl, cyano, halogen, aryl, heteroaryl, heterocyclyl, carbocyclyl, heterocarbocyclyl, sulfmyl, sulfamoyl, or sulfonyl, wherein R 3 is optionally substituted with one or more, the same or different, R 10 ;
  • R 3 and R 3 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 8 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 9 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 7 , R 7 , R 8 , and R 9 can form a ring with the a-carbon they are attached to and the amino group attached to the a-carbon, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 7 and R 7 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 10 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 11 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 9 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4- septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N- dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R’ is deuterium, chloro, iodo, hydroxyl, amino, thiol, alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, heterocarbocyclyl, cycloalkyl, heterocyclyl, or acyl, wherein R’ is optionally substituted with one or more, the same or different, R 10 ;
  • R 1 is selected from H, ed esters, optionally substituted branched esters, optionally substituted carbonates, optionally substituted carbamates, optionally substituted thioesters, optionally substituted branched thioesters, optionally substituted thiocarbonates, optionally substituted S-thiocarbonate, optionally substituted dithiocarbonates, optionally substituted thiocarbamates, optionally substituted oxymethoxy carbonyl, optionally substituted oxymethoxythiocarbonyl, optionally substituted oxymethylcarbonyl, optionally substituted oxymethylthiocarbonyl, L- amino acid esters, D-amino acid esters, N-substituted L-amino acid esters, N,N- disubstituted L-amino acid esters, N-substituted D-amino acid esters, N,N-disubstituted D- amino acid esters, optionally substituted sulfenyl, optionally
  • Y 2 is OH or BH 3 M + ;
  • Y 3 is aryl, heteroaryl, or heterocyclyl, wherein Y 3 is optionally substituted with one or more, the same or different, R 10 ;
  • R 3 is selected from deuterium, alkyl, alkenyl, alkynyl, allenyl, alkoxy, hydroxy, thiol, amino, azido, formyl, acyl, cyano, halogen, aryl, heteroaryl, heterocyclyl, carbocyclyl, heterocarbocyclyl, sulfmyl, sulfamoyl, or sulfonyl, wherein R 3 is optionally substituted with one or more, the same or different, R 10 ;
  • R 3 and R 3 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 5 is hydrogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, allenyl, or lipid, wherein R 5 is optionally substituted with one or more, the same or different, R 10 ;
  • R 6 , R 6 , R 6 , and R 6 are each independently selected from hydrogen, deuterium, hydroxyl, amino, azido, thiol, acyl, formyl, halogen, nitro, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alky
  • R 9 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 7 , R 7 , R 8 , and R 9 can form a ring with the a-carbon they are attached to and the amino group attached to the a-carbon, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 7 and R 7 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 8 and R 9 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 10 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 11 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • Lipid is a C 11 -C 22 higher alkyl, C 11 -C 22 higher alkoxy, polyethylene glycol, or aryl substituted with an alkyl group, or a lipid as described herein.
  • R 6 is hydrogen, hydroxyl, fluoro, chloro, amino, lipid, methyl, methoxy, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert- butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N-dimethylamino, N,N- diethylamino, and N,N-dipropylamino.
  • R 8 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4- septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N- dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 9 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4- septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N- dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • esters optionally substituted branched esters, optionally substituted carbonates, optionally substituted carbamates, optionally substituted thioesters, optionally substituted branched thioesters, optionally substituted thiocarbonates, optionally substituted S-thiocarbonate, optionally substituted dithiocarbonates, optionally substituted thiocarbamates, optionally substituted oxymethoxy carbonyl, optionally substituted oxymethoxythiocarbonyl, optionally substituted oxymethylcarbonyl, optionally substituted oxymethylthiocarbonyl, L- amino acid esters, D-amino acid esters, N-substituted L-amino acid esters, N,N- disubstituted L-amino acid esters, N-substituted D-amino acid esters, N,N-disubstituted D- amino acid esters, optionally substituted sulfenyl, optionally substituted imidate, optionally substituted hydr
  • Y is O or S
  • Y 1 is OH, OY 3 , or BH 3 M + ;
  • Y 3 is aryl, heteroaryl, or heterocyclyl, wherein Y 3 is optionally substituted with one or more, the same or different, R 10 ;
  • R 3 is selected from deuterium, alkyl, alkenyl, alkynyl, allenyl, alkoxy, thiol, amino, azido, formyl, acyl, cyano, halogen, aryl, heteroaryl, heterocyclyl, carbocyclyl, heterocarbocyclyl, sulfmyl, sulfamoyl, or sulfonyl, wherein R 3 is optionally substituted with one or more, the same or different, R 10 ;
  • R 3 and R 3 can form a ring with the carbon they are attached to, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 8 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 9 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 7 , R 7 , R 8 , and R 9 can form a ring with the a-carbon they are attached to and the amino group attached to the a-carbon, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 7 and R 7 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 8 and R 9 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 10 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocycl
  • Lipid is a C 11 -C 22 higher alkyl, C 11 -C 22 higher alkoxy, polyethylene glycol, or aryl substituted with an alkyl group, or a lipid as described herein.
  • R 5 is lipid, methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • the disclosure relates to a compound of Formula XXII,
  • Y 1 is OH, OY 3 , or BH 3 M + ;
  • R 6 , R 6 , R 6 , and R 6 are each independently selected from hydrogen, deuterium, hydroxyl, amino, azido, thiol, acyl, formyl, halogen, nitro, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio,
  • R 8 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 9 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 7 and R 7 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 8 and R 9 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 10 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 11 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • Lipid is a C 11 -C 22 higher alkyl, C 11 -C 22 higher alkoxy, polyethylene glycol, or aryl substituted with an alkyl group, or a lipid as described herein.
  • R 1 is hydrogen
  • R 5 is lipid, methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 6 is hydrogen, hydroxyl, fluoro, chloro, amino, lipid, methyl, methoxy, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert- butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N-dimethylamino, N,N- diethylamino, and N,N-dipropylamino.
  • R 7 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 8 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 9 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 1 is selected from H, esters, optionally substituted branched esters, optionally substituted carbonates, optionally substituted carbamates, optionally substituted thioesters, optionally substituted branched thioesters, optionally substituted thiocarbonates, optionally substituted S-thiocarbonate, optionally substituted dithiocarbonates, optionally substituted thiocarbamates, optionally substituted oxymethoxy carbonyl, optionally substituted oxymethoxythiocarbonyl, optionally substituted oxymethylcarbonyl, optionally substituted oxymethylthiocarbonyl, L- amino acid esters, D-amino acid esters, N-substituted L-amino acid esters, N,N- disubstituted L-amino acid esters, N-substituted D-amino acid esters, N,N-disubstituted D-
  • Y is O or S
  • Y 1 is OH, OY 3 , or BH 3 M + ;
  • R 1 is hydrogen
  • R 5 is lipid, methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 7 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 8 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • the disclosure relates to a compound of Formula XXIV,
  • esters optionally substituted branched esters, optionally substituted carbonates, optionally substituted carbamates, optionally substituted thioesters, optionally substituted branched thioesters, optionally substituted thiocarbonates, optionally substituted S-thiocarbonate, optionally substituted dithiocarbonates, optionally substituted thiocarbamates, optionally substituted oxymethoxy carbonyl, optionally substituted oxymethoxythiocarbonyl, optionally substituted oxymethylcarbonyl, optionally substituted oxymethylthiocarbonyl, L- amino acid esters, D-amino acid esters, N-substituted L-amino acid esters, N,N- disubstituted L-amino acid esters, N-substituted D-amino acid esters, N,N-disubstituted D- amino acid esters, optionally substituted sulfenyl, optionally substituted imidate, optionally substituted hydr
  • Y is O or S
  • Y 1 is OH, OY 3 , or BH 3 M + ;
  • R 6 , R 6 , R 6 , and R 6 are each independently selected from hydrogen, deuterium, hydroxyl, amino, azido, thiol, acyl, formyl, halogen, nitro, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio,
  • R 7 and R 7 are each independently selected from hydrogen, deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalky
  • R 8 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 9 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 7 and R 7 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 8 and R 9 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 10 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 11 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • Lipid is a C 11 -C 22 higher alkyl, C 11 -C 22 higher alkoxy, polyethylene glycol, or aryl substituted with an alkyl group, or a lipid as described herein.
  • R 1 is hydrogen
  • R 9 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • Y 1 is OH, OY 3 , or BH 3 M + ;
  • R 9 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 7 , R 7 , R 8 , and R 9 can form a ring with the a-carbon they are attached to and the amino group attached to the a-carbon, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 8 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 9 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • the disclosure relates to a compound of Formula XXVI,
  • R 1 is selected from H, S , p y ed esters, optionally substituted branched esters, optionally substituted carbonates, optionally substituted carbamates, optionally substituted thioesters, optionally substituted branched thioesters, optionally substituted thiocarbonates, optionally substituted S-thiocarbonate, optionally substituted dithiocarbonates, optionally substituted thiocarbamates, optionally substituted oxymethoxy carbonyl, optionally substituted oxymethoxythiocarbonyl, optionally substituted oxymethylcarbonyl, optionally substituted oxymethylthiocarbonyl, L- amino acid esters, D-amino acid esters, N-substituted L-amino acid esters, N,N- disubstituted L-amino acid esters, N-substituted D-amino acid esters, N,N-disubstitute
  • Y is O or S
  • Y 1 is OH, OY 3 , or BH 3 M + ;
  • R 2 is selected from deuterium, C2-C22 alkyl, alkenyl, alkynyl, allenyl, thiol, amino, azido, formyl, acyl, cyano, chloro, bromo, iodo, aryl, heteroaryl, heterocyclyl, carbocyclyl, heterocarbocyclyl, sulfmyl, sulfamoyl, or sulfonyl, wherein R 2 is optionally substituted with one or more, the same or different, R 10 ;
  • R 6 , R 6 , R 6 , and R 6 are each independently selected from hydrogen, deuterium, hydroxyl, amino, azido, thiol, acyl, formyl, halogen, nitro, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio,
  • R 7 , R 7 , R 8 , and R 9 can form a ring with the a-carbon they are attached to and the amino group attached to the a-carbon, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 7 and R 7 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 10 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 11 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • Y 3 is aryl, heteroaryl, or heterocyclyl, wherein Y 3 is optionally substituted with one or more, the same or different, R 10 ;
  • R 7 and R 7 are each independently selected from hydrogen, deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalky
  • R 8 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 7 and R 7 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 8 and R 9 can form a ring with the a-carbon which they are attached, wherein the ring is optionally substituted with one or more, the same or different, R 10 ;
  • R 10 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • R 11 is deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalken
  • Lipid is a C 11 -C 22 higher alkyl, C 11 -C 22 higher alkoxy, polyethylene glycol, or aryl substituted with an alkyl group, or a lipid as described herein.
  • R is hydrogen
  • R 5 is lipid, methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 6 is hydrogen, hydroxyl, fluoro, chloro, amino, lipid, methyl, methoxy, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert- butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N-dimethylamino, N,N- diethylamino, and N,N-dipropylamino.
  • R 7 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 8 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • R 9 is methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t- hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6- dimethylphenyl, isopropoxide, tert-butoxide, N-propylamino, N-isopropylamino, N-tert- butylamino, N,N-dimethylamino, N,N-diethylamino, and N,N-dipropylamino.
  • the disclosure relates to a compound of Formula XXVIII,
  • R 1 is selected from, substituted esters, optionally substituted branched esters, optionally substituted carbonates, optionally substituted carbamates, optionally substituted thioesters, optionally substituted branched thioesters, optionally substituted thiocarbonates, optionally substituted S- thiocarbonate, optionally substituted dithiocarbonates, optionally substituted thiocarbamates, optionally substituted oxymethoxycarbonyl, optionally substituted oxymethoxythiocarbonyl, optionally substituted oxymethylcarbonyl, optionally substituted oxymethylthiocarbonyl, L-amino acid esters, D-amino acid esters, N-substituted L-amino acid esters, N,N-disubstituted L-amino acid esters, N-substituted D-amino acid esters, N,N- disubstituted D-amino acid esters, N,N- disubstituted D
  • Y is O or S
  • Y 1 is OH, OY 3 , or BH 3 M + ;
  • R 5 is hydrogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, allenyl, or lipid, wherein R 5 is optionally substituted with one or more, the same or different, R 10 ;
  • R 6 , R 6 , R 6 , and R 6 are each independently selected from hydrogen, deuterium, hydroxyl, amino, azido, thiol, acyl, formyl, halogen, nitro, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio,
  • R 7 and R 7 are each independently selected from hydrogen, deuterium, hydroxy, azido, thiol, amino, cyano, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocarbocyclyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy, heteroaryloxy, heterocycloxy, cycloalkoxy, cycloalkenoxy, alkylamino, (alkyl)2amino, carbocyclamino, heterocarbocyclamino, arylamino, heteroarylamino, heterocyclamino, cycloalkamino, cycloalkenamino, alkylthio, carbocyclylthio, heterocarbocyclylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalky
  • Lipid is a C 11 -C 22 higher alkyl, C 11 -C 22 higher alkoxy, polyethylene glycol, or aryl substituted with an alkyl group, or a lipid as described herein.
  • R 6 is hydrogen, hydroxyl, fluoro, chloro, amino, lipid, methyl, methoxy, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, pentyl, s-pentyl, t-pentyl, neopentyl, 3-pentyl, hexyl, t-hexyl, 4-septyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl 2,6-dimethylphenyl, isopropoxide, tert- butoxide, N-propylamino, N-isopropylamino, N-tert-butylamino, N,N-dimethylamino, N,N- diethylamino, and N,N-dipropylamino.
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from: In exemplary embodiments, the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2020/054857 2019-10-08 2020-10-08 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto Ceased WO2021137913A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US17/766,644 US20240165143A1 (en) 2019-10-08 2020-10-08 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
JP2022521355A JP2022551477A (ja) 2019-10-08 2020-10-08 ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用
CN202080069960.7A CN114867351B (zh) 2019-10-08 2020-10-08 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途
EP20908968.9A EP4040965A4 (en) 2019-10-08 2020-10-08 THERAPEUTIC COMPOSITIONS BASED ON NUCLEOSIDES AND NUCLEOTIDES CONTAINING 4-HALOGEN AND ASSOCIATED USES
AU2020418425A AU2020418425A1 (en) 2019-10-08 2020-10-08 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN202410413848.0A CN118477090A (zh) 2019-10-08 2020-10-08 含4'-卤素的核苷酸和核苷治疗组合物以及其相关用途
CA3153281A CA3153281A1 (en) 2019-10-08 2020-10-08 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US19/292,470 US20260102422A1 (en) 2019-10-08 2025-08-06 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
JP2025172129A JP2026027247A (ja) 2019-10-08 2025-10-10 ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962912165P 2019-10-08 2019-10-08
US62/912,165 2019-10-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US17/766,644 A-371-Of-International US20240165143A1 (en) 2019-10-08 2020-10-08 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US19/292,470 Continuation US20260102422A1 (en) 2019-10-08 2025-08-06 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Publications (2)

Publication Number Publication Date
WO2021137913A2 true WO2021137913A2 (en) 2021-07-08
WO2021137913A3 WO2021137913A3 (en) 2021-09-30

Family

ID=76686993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/054857 Ceased WO2021137913A2 (en) 2019-10-08 2020-10-08 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Country Status (7)

Country Link
US (2) US20240165143A1 (https=)
EP (1) EP4040965A4 (https=)
JP (2) JP2022551477A (https=)
CN (2) CN118477090A (https=)
AU (1) AU2020418425A1 (https=)
CA (1) CA3153281A1 (https=)
WO (1) WO2021137913A2 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113929724A (zh) * 2021-11-02 2022-01-14 周雨恬 一种核苷类化合物及其药物组合物和用途
US11312743B1 (en) * 2021-03-20 2022-04-26 Optimus Drugs Private Limited Process for molnupiravir
WO2024123207A1 (ru) * 2022-12-08 2024-06-13 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации 5'-о-(3-фенилпропионил)-n4-гидроксицитидин и его применение
WO2024123206A1 (ru) * 2022-12-08 2024-06-13 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Способ получения 5',-о-(3-фенилпропионил)-n4-гидроксицитидина
WO2025014360A1 (en) * 2023-07-07 2025-01-16 Erasmus University Medical Center Rotterdam Guanosine nucleotide analogs for use in preventing and/or treating hepatitis e virus infection
JP2025513500A (ja) * 2022-04-20 2025-04-24 シャンハイ インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ 抗ウイルスヌクレオシド類似体並びにその医薬組成物及び使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710492A (en) * 1986-06-23 1987-12-01 Yale University 3'-azido-2',3'-dideoxy-5-halouridine and its use in treating patients infected with retroviruses
EP1674104A1 (en) * 2004-12-24 2006-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV
JP6165848B2 (ja) * 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのｄ−アミノ酸化合物
AU2014302711A1 (en) * 2013-06-26 2015-12-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015054465A1 (en) * 2013-10-11 2015-04-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HUE051986T2 (hu) * 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
KR20200140274A (ko) * 2018-03-07 2020-12-15 에모리 유니버시티 4'-할로겐 함유 뉴클레오티드 및 뉴클레오시드 치료 조성물 및 이와 관련된 용도

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11312743B1 (en) * 2021-03-20 2022-04-26 Optimus Drugs Private Limited Process for molnupiravir
CN113929724A (zh) * 2021-11-02 2022-01-14 周雨恬 一种核苷类化合物及其药物组合物和用途
CN113929724B (zh) * 2021-11-02 2024-05-31 周雨恬 一种核苷类化合物及其药物组合物和用途
JP2025513500A (ja) * 2022-04-20 2025-04-24 シャンハイ インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ 抗ウイルスヌクレオシド類似体並びにその医薬組成物及び使用
WO2024123207A1 (ru) * 2022-12-08 2024-06-13 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации 5'-о-(3-фенилпропионил)-n4-гидроксицитидин и его применение
WO2024123206A1 (ru) * 2022-12-08 2024-06-13 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Способ получения 5',-о-(3-фенилпропионил)-n4-гидроксицитидина
WO2025014360A1 (en) * 2023-07-07 2025-01-16 Erasmus University Medical Center Rotterdam Guanosine nucleotide analogs for use in preventing and/or treating hepatitis e virus infection

Also Published As

Publication number Publication date
WO2021137913A3 (en) 2021-09-30
AU2020418425A1 (en) 2022-04-14
EP4040965A2 (en) 2022-08-17
EP4040965A4 (en) 2023-11-08
CN114867351A (zh) 2022-08-05
CN114867351B (zh) 2024-04-23
CA3153281A1 (en) 2021-07-08
US20240165143A1 (en) 2024-05-23
US20260102422A1 (en) 2026-04-16
CN118477090A (zh) 2024-08-13
JP2022551477A (ja) 2022-12-09
JP2026027247A (ja) 2026-02-18

Similar Documents

Publication Publication Date Title
US20240180948A1 (en) 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US20260053838A1 (en) Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections
WO2022174194A1 (en) 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US20260102422A1 (en) 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US11192914B2 (en) Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US20190085013A1 (en) Nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2022174179A9 (en) 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
RU2819040C2 (ru) Терапевтические композиции 4’-галогенсодержащих нуклеотидов и нуклеозидов и их применение
US20260124226A1 (en) 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2024086592A2 (en) 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
AU2024267852A1 (en) 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
HK40123809A (zh) 含4'-卤素的核苷酸和核苷治疗组合物以及其相关用途
EA047160B1 (ru) Терапевтические композиции 4'-галогенсодержащих нуклеотидов и нуклеозидов и их применение

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20908968

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3153281

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022521355

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020418425

Country of ref document: AU

Date of ref document: 20201008

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020908968

Country of ref document: EP

Effective date: 20220509

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20908968

Country of ref document: EP

Kind code of ref document: A2